Inimmune Corporation
CompanyUnited States
Inimmune Corporation develops one asset, in phase 1 (INI-4001 in advanced solid tumor). Mostly small molecule acting on TLR7; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 1
- Signal
Pipeline
1Activates TLR7 and TLR8 to stimulate cytokine production and antitumor immune responses.
Phase 1, Small molecule, TLR7, advanced solid tumor
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals2
- Similar companies6